ACTOv clinical trial

[OvacomeSupport]

Hello All

We've been asked to share the following information regarding a clinical trial:

ACTOv is a clinical trial investigating a new personalised treatment approach to treat ovarian cancer that has relapsed (returned after previously receiving platinum chemotherapy treatment). The new treatment approach, known as ‘Adaptive Therapy (AT)’, aims to prevent the cancer from becoming resistant to chemotherapy, whilst also reducing side effects. AT involves changing the dose of chemotherapy given to an individual participant based on how their tumour responds to the treatment over time.

How a tumour responds to treatment is assessed using a protein called CA125 which is found in the blood of ovarian cancer patients.

In AT if the level of CA125 has decreased, the carboplatin dose will be reduced at the next treatment cycle; and if the level of CA125 has increased, then the carboplatin dose will be increased at the next treatment cycle.

TRIAL DESIGN

ACTOv is a randomised trial, meaning that participants will be allocated to one of the two trial groups by a computer at random with a 50/50 chance of being in either group. There will be 40 patients in both groups

1. STANDARD THERAPY (CONTROL): In this group, participants receive the usual standard of care, which is six cycles of the same standard dose of carboplatin.

2. ADAPTIVE THERAPY (AT): In the AT group, participants receive twelve cycles with tailored doses of carboplatin depending on their individual response to the treatment. Response to treatment will be measured after each treatment cycle using a blood test to determine the level of CA125 present in the blood.

All participants taking part in the trial will be followed up by the trial team every 3 months for 1 year after the end of their last trial treatment.

HOW TO TAKE PART

The ACTOv trial is currently open to recruitment at the following hospitals in the UK:

• University College London Hospital (UCLH), London

• St Bartholomew’s Hospital, London

• Western General Hospital, Edinburgh

• The Christie Hospital, Manchester

• Clatterbridge Cancer Centre, Wirral

• Velindre Cancer Centre, Cardiff

• Royal Sussex County Hospital, Brighton

• Worthing Hospital, Worthing

• Royal United Hospital, Bath

The trial team are planning to open the trial at a further 2 UK sites over the coming months.

If you are interested in taking part in the ACTOv trial, please speak to your doctor to discuss your options and see if you would be eligible to take part.

LINKS TO FURTHER INFORMATION

• CRUK & UCL CTC Website: ctc.ucl.ac.uk/TrialDetails....

• Anticancer Fund Website: anticancerfund.org/adaptive...

• Barts Charity Website: bartscancer.london/general-...

Best wishes

Anna

Ovacome Support

[Cardiff05]

Approached UCL on two separate occasions and several months ago regards criteria for inclusion email lead researcher and research team for further information.

Never even received a response or even an acknowledgement.

Is there any wonder there still seeking candidates several months after the trial started?

[OvacomeSupport Partner My Ovacome Team in reply to Cardiff05]

Dear Cardiff05

We're really sorry to hear about the difficulties you've had contacting the trial team. The key inclusion/exclusion criteria is listed here, if this is any help:

ctc.ucl.ac.uk/TrialDetails.... There's an email address on that page too, if you want to see if it was the same one you/your oncologist were using previously?

If you need any further information or if there is anything we can help with, please do let us know. You can direct message through this forum, email [e-mail] or call us on 0800 008 7054 Monday-Friday 10am-5pm.

Best wishes

Anna

Ovacome Support